BACKGROUND:Schizophrenic patients exhibit impairments in prepulse inhibition (PPI) and habituation of the acoustic startle response (ASR). Recent studies suggested that PPI deficits and habituation deficits are normalized after antipsychotic treatment. Despite clear evidence of gating and habituation mechanisms in animal models, it is still unknown which neurotransmitter systems are involved in schizophrenic patients. Thus, we compared the effects of a combined 5-HT2A/D2 and a pure D2/D3 antagonist on PPI and habituation of ASR in patients with schizophrenia. METHODS: The ASR was measured in 37 acute schizophrenic patients who were randomized and double-blinded as to treatment with amisulpride or olanzapine. Patients were assessed during the first week and after four and eight weeks of treatment. Twenty healthy matched control subjects were examined likewise. RESULTS:Schizophrenic patients showed a significant PPI deficit and significantly decreased startle amplitude at baseline. The gating deficit disappeared after antipsychotic treatment in both treatment groups. Amisulpride sensitized the startle amplitude, whereas startle amplitude was not changed by olanzapine. After correcting for startle amplitude, patients did not show a habituation deficit; however, amisulpride accelerated habituation, whereas olanzapine had no effect. CONCLUSIONS: Our findings suggest that the PPI-restoring effect of antipsychotics is probably attributed to a dopamine D2 receptor blockade.
RCT Entities:
BACKGROUND:Schizophrenicpatients exhibit impairments in prepulse inhibition (PPI) and habituation of the acoustic startle response (ASR). Recent studies suggested that PPI deficits and habituation deficits are normalized after antipsychotic treatment. Despite clear evidence of gating and habituation mechanisms in animal models, it is still unknown which neurotransmitter systems are involved in schizophrenicpatients. Thus, we compared the effects of a combined 5-HT2A/D2 and a pure D2/D3 antagonist on PPI and habituation of ASR in patients with schizophrenia. METHODS: The ASR was measured in 37 acute schizophrenicpatients who were randomized and double-blinded as to treatment with amisulpride or olanzapine. Patients were assessed during the first week and after four and eight weeks of treatment. Twenty healthy matched control subjects were examined likewise. RESULTS:Schizophrenicpatients showed a significant PPI deficit and significantly decreased startle amplitude at baseline. The gating deficit disappeared after antipsychotic treatment in both treatment groups. Amisulpride sensitized the startle amplitude, whereas startle amplitude was not changed by olanzapine. After correcting for startle amplitude, patients did not show a habituation deficit; however, amisulpride accelerated habituation, whereas olanzapine had no effect. CONCLUSIONS: Our findings suggest that the PPI-restoring effect of antipsychotics is probably attributed to a dopamine D2 receptor blockade.
Authors: Erin A Hazlett; Monte S Buchsbaum; Jing Zhang; Randall E Newmark; Cathryn F Glanton; Yuliya Zelmanova; M Mehmet Haznedar; King-Wai Chu; Igor Nenadic; Eileen M Kemether; Cheuk Y Tang; Antonia S New; Larry J Siever Journal: Neuroimage Date: 2008-07-11 Impact factor: 6.556
Authors: Neal R Swerdlow; Gregory A Light; Joyce Sprock; Monica E Calkins; Michael F Green; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Laura C Lazzeroni; Keith H Nuechterlein; Allen D Radant; Amrita Ray; Larry J Seidman; Larry J Siever; Jeremy M Silverman; William S Stone; Catherine A Sugar; Debby W Tsuang; Ming T Tsuang; Bruce I Turetsky; David L Braff Journal: Schizophr Res Date: 2014-01-07 Impact factor: 4.939
Authors: Wendy Hasenkamp; Michael P Epstein; Amanda Green; Lisette Wilcox; William Boshoven; Barbara Lewison; Erica Duncan Journal: Psychiatry Res Date: 2010-05-16 Impact factor: 3.222
Authors: Natalia I Brzozowska; Erik J de Tonnerre; Kong M Li; Xiao Suo Wang; Aurelie A Boucher; Paul D Callaghan; Michael Kuligowski; Alex Wong; Jonathon C Arnold Journal: Neuropsychopharmacology Date: 2017-03-08 Impact factor: 7.853
Authors: Kathy L Kohlhaas; Robert S Bitner; Murali Gopalakrishnan; Lynne E Rueter Journal: Psychopharmacology (Berl) Date: 2011-10-29 Impact factor: 4.530
Authors: Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff Journal: Psychopharmacology (Berl) Date: 2008-06-21 Impact factor: 4.530
Authors: Wolfgang Maier; Rainald Mössner; Boris B Quednow; Michael Wagner; René Hurlemann Journal: Eur Arch Psychiatry Clin Neurosci Date: 2008-11 Impact factor: 5.270